ArticleClinical and molecular hepatology2026

Challenges and innovations in MASLD and T2DM: Strengthening personalized medicine with SGLT2 inhibitors: Editorial on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis".

Yang-Hsiang Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.